Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCC-3009 in GIST
NCT06630234Phase 2Recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dcc-3009 in gastrointestinal stromal tumor (GIST), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicities at 28 days and Objective Response Rate at 24 months. Started Dec 2024; status: recruiting.
02
Drugs
dcc-3009
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT06630234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630234.